002166 莱茵生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入725,48941.65%1,493,9301,400,7371,053,235783,671
减:营业总成本657,85230.89%1,406,2181,176,598933,946716,004
    其中:营业成本518,02233.71%1,129,188969,329739,325565,225
               财务费用12,052116.77%24,4297,85825,42514,115
               资产减值损失223-121.42%(44,290)(23,262)(6,161)(5,842)
公允价值变动收益(4,503)-116.06%45,34836,80812,54116,078
投资收益7,36327.81%4,8282,7764,4371,463
    其中:对联营企业和合营企业的投资收益------------
营业利润86,94163.39%118,321253,690151,95499,348
利润总额81,46855.52%116,363238,336151,93798,967
减:所得税费用13,47351.04%18,01750,04420,75212,789
净利润67,99556.44%98,346188,292131,18586,178
减:非控股权益3,102-57.31%15,8359,55512,747188
股东净利润64,89379.28%82,511178,738118,43885,989

市场价值指针
每股收益 (元) *0.09080.00%0.1100.2900.2100.150
每股派息 (元) *----0.2000.100--0.050
每股净资产 (元) *4.053-1.69%4.2204.1303.3063.168
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容